Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.…Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.WWW…
Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.…Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.WWWW…
Available to hire
$250 per day ($31.25 per hour)
Founded in 1999, BGI is one of the world’s leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people’s livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.
Skills
Fr
First Prospective Study in China for More Effective Ovarian Cancer Treatment l BGI Perspectives
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a biomarker in ovarian cancer patients, especially in the Chinese population.
This first-ever China prospective cohort study, jointly conducted by BGI Genomics clinical researcher Dr. Shao Di and the Fudan University Shanghai Cancer Center team and published on the Journal of Ovarian Research indicates that HRD testing can accurately predict the sensitivity of platinum-based chemotherapy for ovarian cancer patients.
Research Method
The study covered 240 patients with primary treatment of high-grade serious ovarian cancer (HGSOC) admitted to the Cancer Hospital of Fudan University from January 2016 to September 2018 interval. Patients received more than two cycles of platinum-containing adjuvant chemotherapy after surgery and were classified as platinum-sensitive (Pt) and platinum-resistant according to the time of ovarian cancer recurrence.
All patients were tested with a gene panel test screening for 68 HRR genes, to assess the mutation status of HRR-related genes such as BRCA. Of these, 118 samples underwent the HRD test to assess loss of heterozygosity (LOH), telomere allele disequilibrium (TAI), and large segmental recombination abnormality (LST) status. The Kaplan-Meier method was used to plot survival curve and the effectiveness of these tests in predicting patient outcomes.
Conclusion
This study demonstrated for the first time that HRD is a valid biomarker tool for predicting sensitivity to platinum-based chemotherapy in prospective cohort unselected Chinese ovarian cancer patients.
The study also found a higher rate of HRD positivity in Chinese ovarian cancer patients than in Western populations, suggesting that HRD testing could screen a higher proportion of Chinese PARP inhibitor population to facilitate precision therapy.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.
Additional Readings:
https://www.twine.net/signin
https://www.twine.net/signin
https://www.twine.net/signin
#bgichina #bgigenetest…Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a biomarker in ovarian cancer patients, especially in the Chinese population.
This first-ever China prospective cohort study, jointly conducted by BGI Genomics clinical researcher Dr. Shao Di and the Fudan University Shanghai Cancer Center team and published on the Journal of Ovarian Research indicates that HRD testing can accurately predict the sensitivity of platinum-based chemotherapy for ovarian cancer patients.
Research Method
The study covered 240 patients with primary treatment of high-grade serious ovarian cancer (HGSOC) admitted to the Cancer Hospital of Fudan University from January 2016 to September 2018 interval. Patients received more than two cycles of platinum-containing adjuvant chemotherapy after surgery and were classified as platinum-sensitive (Pt) and platinum-resistant according to the time of ovarian cancer recurrence.
All patients were tested with a gene panel test screening for 68 HRR genes, to assess the mutation status of HRR-related genes such as BRCA. Of these, 118 samples underwent the HRD test to assess loss of heterozygosity (LOH), telomere allele disequilibrium (TAI), and large segmental recombination abnormality (LST) status. The Kaplan-Meier method was used to plot survival curve and the effectiveness of these tests in predicting patient outcomes.
Conclusion
This study demonstrated for the first time that HRD is a valid biomarker tool for predicting sensitivity to platinum-based chemotherapy in prospective cohort unselected Chinese ovarian cancer patients.
The study also found a higher rate of HRD positivity in Chinese ovarian cancer patients than in Western populations, suggesting that HRD testing could screen a higher proportion of Chinese PARP inhibitor population to facilitate precision therapy.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.
Additional Readings:
https://www.twine.net/signin
https://www.twine.net/signin
https://www.twine.net/signin
#bgichina #bgigenetestWW…
Comparing US-China Colorectal Cancer Screening l BGI Perspectives
In recent years, cancer has become one of the major public health issues seriously threatening the Chinese population. According to the latest global cancer-related data for 2020 released by the International Agency for Research on Cancer (IARC) of the World Health Organization, 19.29 million new cancer cases and 9.96 million cancer-related deaths will occur.
The number of new cancer cases far exceeds that of other countries in the world. According to the latest data released by the National Cancer Center in 2022, China spends more than $220 billion on cancer-related medical treatment each year, and the overall 5-year survival rate of cancer in China is significantly worse than that of developed countries, making the prevention and control situation very serious.
Early cancer screening is an effective way to detect cancer and precancerous lesions at an early stage, playing a crucial role in the whole cycle of detection and treatment by screening out cancer-risk groups or cancer-positive patients from an asymptomatic population with fast and effective methods. Today, we will take colorectal cancer prevention and control and introduce U.S. and China's developments in early screening for colorectal cancer.
Additional Readings:
https://www.twine.net/signin
https://www.twine.net/signin
https://www.twine.net/signin
About BGI Genomics:
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. BGI has topped the Asia Pacific and China life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables.
#bgichina #bgigenetest…In recent years, cancer has become one of the major public health issues seriously threatening the Chinese population. According to the latest global cancer-related data for 2020 released by the International Agency for Research on Cancer (IARC) of the World Health Organization, 19.29 million new cancer cases and 9.96 million cancer-related deaths will occur.
The number of new cancer cases far exceeds that of other countries in the world. According to the latest data released by the National Cancer Center in 2022, China spends more than $220 billion on cancer-related medical treatment each year, and the overall 5-year survival rate of cancer in China is significantly worse than that of developed countries, making the prevention and control situation very serious.
Early cancer screening is an effective way to detect cancer and precancerous lesions at an early stage, playing a crucial role in the whole cycle of detection and treatment by screening out cancer-risk groups or cancer-positive patients from an asymptomatic population with fast and effective methods. Today, we will take colorectal cancer prevention and control and introduce U.S. and China's developments in early screening for colorectal cancer.
Additional Readings:
https://www.twine.net/signin
https://www.twine.net/signin
https://www.twine.net/signin
About BGI Genomics:
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. BGI has topped the Asia Pacific and China life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables.
#bgichina #bgigenetestWW…
BGI China | BGI Signing Ceremony in Poznan, Poland
BGI signing ceremony in Poznan, Poland
with witness of Mayor of Shenzhen (China)
and Poznań City (Polen)
March 2014 #video #advert #organization…BGI signing ceremony in Poznan, Poland
with witness of Mayor of Shenzhen (China)
and Poznań City (Polen)
March 2014 #video #advert #organizationWW…
Hire a Actor
We have the best actor experts on Twine. Hire a actor in Shenzhen today.